Shows
Gedankensprünge#47 | Die 90er JahreWas haben Sie uns gebracht?
Was war, was ist, was bleibt? In einer neuen Serie widmet sich unser Podcast einzelnen Jahrzehnten und ihren Errungenschaften. Was waren die prägenden historischen Ereignisse, wie war die gesellschaftliche Stimmung, und welche Veränderungen wurden angestoßen? Was haben wir aus der Vergangenheit gelernt, was vermissen wir, und was können wir getrost hinter uns lassen? In dieser Folge blicken wir zurück auf die 90er Jahre und sprechen mit einer Volkswirtin, einem Urologen, einem Politikwissenschaftler und einer Bassistin.
Prof. Dr. Karen Cabos (TH) war in den 90er Jahren ganz nah dran am finanzpolitischen Gesch...
2025-03-191h 06
GU Cast | Urology PodcastShanghai GU Oncology Highlights Part 2Part 2 of our GU Cast Conference Highlights from Shanghai including discussions with Dr Stephen Freedland (Los Angeles), Dr Liang Liang (Shaanxi), Dr Andrea Necchi (Milano), Dr Xiaojie Bian (Shanghai), and Dr Hongkai Wang (Shanghai). Declan Murphy travelled to Shanghai for the 14th GU Oncology Academic Meeting hosted by Fudan University Shanghai Cancer Centre, and to meet up with our GU Cast China Editor, Dr Yao Zhu. This is an excellent meeting in one of our very favourite cities. In Part 1 we spoke to Conference Chair, Dr Dingwei Ye, Dr Karim Fizazi, Dr Peng Wu, and Dr Axel Merseburger, to o...
2025-01-0940 minGU Cast | Urology PodcastShanghai GU Oncology Highlights Part 1Declan Murphy travels to Shanghai for the 14th GU Oncology Academic Meeting hosted by Fudan University Shanghai Cancer Centre, and to meet up with our GU Cast China Editor, Dr Yao Zhu. This is an excellent meeting in one of our very favourite cities, and this year Declan joins International Faculty including Dr Stephen Freedland (Los Angeles), Dr Karim Fizazi (Paris), Dr Axel Merseburger (Lubeck). and Dr Andrea Necchi (Milano) to overview the latest stories in GU Oncology. Top Chinese experts from across the country also join and the meeting includes some landmark consensus statements from multidisciplinary panels....
2025-01-0435 minGU Cast | Urology PodcastPSA and Testosterone | Why low numbers matterHow often do you check PSA and testosterone in your patients on androgen deprivation therapy? Probably not often enough!! Declan caught up with friend of the podcast Professor Axel Merseburger at a conference recently to chat about this under-appreciated topic. Don't get too distracted by fancy scans and genomic testing; but do make sure you know a bit about why it matters to get testosterone (and PSA) as low as possible. This is a Themed Podcast supported by our Gold Partners, Mundipharma. Even better on our YouTube channel
2024-08-2720 minGU Cast | Urology PodcastHigh risk prostate cancer and mHSPC | With Axel MerseburgerAxel Merseburger (Chief and Professor of Urology, Lubeck, Germany) was in Australia recently and popped into the GU Cast studio for a chat. Axel was at the USANZ ASM recently and also on a speaker tour supported by Janssen Pharmaceuticals, so we put together this Themed Podcast to pick his brains on high-risk prostate cancer and mHSPC in 2024. This Themed Podcast is supported by Janssen Pharmaceuticals, Gold Partners of GU Cast. Even better on our YouTube channel
2024-03-1926 minGU Cast | Urology Podcast#USANZ24 Conference HighlightsDeclan and Renu bring you lots of highlights and interviews from the Urological Society of Australia & New Zealand (USANZ) Annual Scientific Meeting (ASM) which took place last week in Adelaide. Almost 1000 delegates descended on this beautiful part of the world, famous for its beaches and wineries. Hear from Robert Nam, Paul Anderson, Nathan Lawrentschuk, Alan McNeill, Axel Merseburger, Dixon Woon, Michael Choong, Jo Cresswell, Anthony Ta, and Shane La Bianca who is Convenor of #USANZ25. GU Cast Conference Highlights are supported by Bayer Pharmaceuticals (China), GU Cast Conference Highlights Partner. Even better on our YouTube channel
2024-03-0459 min
touchPODCASTAdverse event identification and management in locally advanced/metastatic urothelial carcinomatouchPANEL DISCUSSION for touchONCOLOGY
Listen to an oncologist, urologist and nurse discuss adverse event identification and management with immunotherapies and targeted therapies for locally advanced or metastatic urothelial carcinoma.
The experts:
Dr Axel Merseburger, University Hospital Schleswig-Holstein, Campus Lübeck, Germany
Dr André Fay, PUCRS School of Medicine, Porto Alegre, Brazil
Ms Maria Lapuente, St Bartholomew’s Hospital, London, UK
This touchPODCAST is for HCPs outside the US only.
This activity is funded by an independent medical education grant from Astellas Inc. and Seagen Inc., and is jointly provided by USF He...
2023-05-3139 min
Patho?Logisch!Prostatakrebs - Ein Interview mit dem Urologen Prof. Axel MerseburgerProstatakrebs - Ein Interview mit dem Urologen Prof. Axel Merseburger
Kritik/Anregungen:
perner@hp-hamburg.de
christiane.kuempers@uksh.de
2023-01-2418 minPatho?Logisch!Prostatakrebs - Ein Interview mit dem Urologen Prof. Axel MerseburgerProstatakrebs - Ein Interview mit dem Urologen Prof. Axel Merseburger
Kritik/Anregungen:
perner@hp-hamburg.de
christiane.kuempers@uksh.de
2023-01-2418 min
The UromigosEpisode 202: The Uromigos Paper of the Month - Docetaxel with or without continuous enza in CRPCAxel Merseburger describes the results of this randomised trial in Lancet Oncology.
2022-11-0723 mintouchPODCASTAdvances in immunotherapies and targeted treatments for patients with bladder cancer: An update from ESMO 2022touchCONGRESS for touchONCOLOGY
Listen to urological cancer expert Prof. Axel Merseburger (Germany) review key data presented at ESMO 2022 exploring recent advances in immunotherapies and targeted treatments for patients with bladder cancer. He then offers his views on the potential impact of these data on clinical practice, alongside expert insights from Dr Bradley McGregor (USA) and Prof. Andrea Necchi (Italy).
OVERVIEW
Data Review with Prof. Merseburger (00:00)
Expert interviews with Prof. Merseburger, Dr McGregor and Prof. Necchi answering the questions below
INTERVIEW QUESTIONS
Based on data recently presented at...
2022-10-0358 min
Health NattersErfahrung trifft Geschichten: Digital Opinion Leader - Part II: Nicole im Gespräch mit Prof. MerseburgerProf. Axel Merseburger gehört zu den klassischen Key Opinion Leadern in der Urologie/Uro-Onkologie. Er hat mittlerweile aber auch eine relevante digitale Reichweite aufgebaut – auf Twitter mit der klaren Zielsetzung die eigene Peer Group also Fachärzte zu erreichen. Warum Social Media Kommunikation gerade in der Information und Education zu wissenschaftlichen Inhalten wichtig ist? Wie es im Spannungsfeld mit der pharmazeutischen Industrie aussieht und warum Social Media auch mal ausgeschaltet werden muss? Antworten dazu in dieser Podcast-Folge.Axel S. Merseburger (@amerseburger) / Twitter
2022-06-1625 mintouchPODCASTExtending the benefit of PARP inhibitors through combinations for advanced prostate cancer - Conversation 3touchMDT for touchONCOLOGY
Listen to a medical oncologist, a urologist and an oncology pharmacist discuss extending the benefit of PARP inhibitors through combinations for the treatment of advanced prostate cancer.
The multidisciplinary team
Medical Oncologist: Dr Wassim Abida, USA
Urologist: Professor Axel Merseburger, Germany
Oncology Pharmacist: Dr Lisa Holle, USA
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Pfizer. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitor-combinations-in-advanced-prostate-cancer/
...
2022-05-0512 mintouchPODCASTPARP inhibitor combination clinical trials for advanced prostate cancer - Conversation 2touchMDT for touchONCOLOGY
Listen to a urologist and a medical oncologist discuss key clinical trials investigating PARP inhibitor combinations for the treatment of advanced prostate cancer.
The multidisciplinary team
Urologist: Professor Axel Merseburger, Germany
Medical Oncologist: Dr Wassim Abida, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Pfizer. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitor-combinations-in-advanced-prostate-cancer/
2022-05-0512 min
UROlogisch!Zu Gast bei Wülfing: Dr. med. Marie Roesch und Prof. Dr. med. Axel MerseburgerUrothelkarzinom: Zwischen Leitlinien und Freiräumen
Es bewegt sich viel beim Urothelkarzinom. Seit einiger Zeit sorgen immuntherapeutische Optionen für Aufsehen und neue Hoffnung bei Patienten. Christian Wülfing bespricht das in Folge 13 mit gleich zwei Gästen, Dr. Marie Roesch und Prof. Dr. Axel Merseburger, beide vom Universitätsklinikum Schleswig-Holstein in Lübeck. Zwar ist weiterhin die Cisplatin-haltige Chemotherapie der Goldstandard für das metastasierte Urothelkarzinom in der Erstlinie. Sind die Patienten allerdings dafür nicht geeignet, gibt es nun immuntherapeutische Optionen, Pembrolizumab und Atezolizumab. In der Zweitlinie spielen die Immuntherapeutika ebenfalls eine siginifikante Rolle. die beiden Gäste führen ko...
2021-10-0426 min
Katheterkollegen - der Urologie PodcastOf Hormones and Men - die Hormontherapie des Prostatakarzinoms
Dieses Mal geht es bei den Katheterkollegen um die Hormontherapie des
Prostatakarzinoms. Das Expertenduo Prof. Gunhild von Amsberg (Hamburg) und Prof. Axel Merseburger (Lübeck) erklären die Indikationen im metastasierten und nicht-metatasierten Stadium, Wirkung und Nebenwirkungen der unterschiedlichen Präparate und aktuelle sowie mittlerweile weniger aktuelle Therapieoptionen. Auch wenn längst noch nicht alle Fragen rund um dieses Thema beantwortet sind, geben die beiden Expert*innen einen sehr guten Einstieg in das Thema und schaffen eine Übersicht für Assistentinnen und Assistenten. Viel Spaß beim Anhören!
2020-10-2942 min
Medicine Matters oncologyManaging patients with genitourinary cancers in the time of COVID-19 (with Cora Sternberg)Genitourinary oncologists Cora Sternberg (Weill Cornell Medicine, New York, USA) and Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) share their experience of managing cancer patients during the COVID-19 pandemic, comparing perspectives from a US and German stand point. Find more on Medicine Matters oncology
2020-03-2500 min